Thought Leader Insight & Analysis Report - Breast Cancer Q1 2010

Medpredict, March 2010, Pages: 143

In this report, the 24th in our Oncology series we summarize the perspectives of six world-class experts in the treatment of breast cancer. In this report they provide their opinions on standards of care today and their expectations for experimental therapeutics. The Panel deals with a number of issues that are important to companies trying to differentiate their new drugs within a very crowded space, including strategies and clinical trial designs that will help to leapfrog more advanced competitors. They reveal the key indications worth pursuing, and the classes of drugs that can produce meaningful survival advantages for women with these breast cancers.

This report provides essential KOL insight for key stakeholders in the breast cancer market at a significant value versus customized primary research

Executive Summary

Top-Ten Report Highlights
- Breast Cancer Unmet Needs
- Angiogenesis inhibitors
- Antimitotics: Taxane / Epothilone / Vinca / 5FU
- Antiresorptives
- GPNMB
- HER2
- HER2 / EGFR
- IGF-1
- PARP
- PI3K / RAS / mTOR / AKT / MEK
- Key Findings
- Breast Cancer Unmet Needs
- High Risk Adjuvant
- 1st-line Metastatic Breast Cancer
- 2nd-line / 3rd-line / Salvage Metastatic Breast Cancer
- Estrogen Receptor Positive
- Triple Negative
- Genomics / Biomarkers
- Pharmacotherapies (Alphabetical by Target)
- Angiogenesis inhibitors
- Avastin; bevacizumab (Genentech)
- Nexavar; sorafenib (Bayer-Schering/Onyx)
- Sutent; sunitinib (Pfizer)
- Antimitotics: Taxane / Epothilone / Vinca / 5FU
- Abraxane; nab-paclitaxel (Abraxis)
- eribulin; E7389 (Eisai)
- Ixempra; ixabepilone (Bristol-Myers Squibb)
- Xeloda; capecitabine (Roche)
- Xyotax; a.k.a. Opaxio (Cell Therapeutics)
- Antiresorptives
- Prolia; denosumab (Amgen), Zometa; zoledronic acid (Novartis); Bonefos; clodronate (Bayer-Schering)
- Bcl2
- ABT-737 (Abbott)
- GPNMB
- CDX-011; CR011-vcMMAE (Celldex)
- HER2
- Herceptin; trastuzumab (Genentech)
- Omnitarg; pertuzumab (Genentech)
- trastuzumab-DM1; T-DM1 (Genentech / ImmunoGen)
- HER2 / EGFR
- Tykerb; lapatinib (GlaxoSmithKline)
- neratinib; HKI-272 (Pfizer)
- HER3
- MM-121 (Sanofi-Aventis / Merrimack)
- Hormonal Therapy
- Aromasin; exemestane (Pfizer), Femara; letrozole (Novartis)
- IGF1
- AMG 479 (Amgen)
- dalotuzumab; MK-0646 (Merck)
- figitumumab; CP-751871 (Pfizer)
- PARP
- olaparib; AZD2281 (AstraZeneca), ABT-888 (Abbott), MK-4827 (Merck), AG014699 (Pfizer)
- BSI-201 (BiPar Sciences / Sanofi-Aventis)
- MK-4827 (Merck), AG014699 (Pfizer)
- PI3K / RAS / mTOR / AKT / MEK
- 690693; AKT (GlaxoSmithKline)
- Afinitor; everolimus (Novartis)
- BEZ-235, BGT-226 (Novartis)
- MK-2206 (Merck) / AZD6244 (AstraZeneca)
- ridaforolimus; deforolimus; MK-8806; AP-23573 (Merck / Ariad)
- XL-147, XL-765 (Exelixis / Sanofi-Aventis)
- WT1
- Antigen Specific WT1; GlaxoSmithKline

Thought Leader Interviews
- Interview OHIID02395
- Interview OHIID02396
- Interview OHIID02397
- Interview OHIID02398
- Interview OHIID02399
- Interview OHIID02400

Please see brochure

Product Samples

A sample for this product is available. Please Login/Register to download this sample.

Customers who bought this item also bought

• Gastroenterology - Thought Leader Panel 2012
• Competitor Analysis - PI3K-AKT-mTOR Inhibitors
• Melanoma - Thought Leader Panel 2012
• Thought Leader Insight & Analysis Report - Psoriasis Q4 2011
• Positioning of Current and Emerging Targeted Agents in Breast Cancer: Physician & Payer Perspective on Treatment and Reimbursement Decisions in Europe
• Small Molecule Kinase Inhibitors - Global Strategic Business Report
• Competitor Analysis: Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors
• Global Biopharma Outlook 2012 - Major US and EU Pharma
• Competitor Analysis - Cancer Antibodies in Early Clinical Development
• Gastric Cancer (Event Driven)